Teva Advances TEV-'408 Into Phase 2b for Vitiligo

Teva Pharmaceutical Industries announced today that it will advance TEV-'408, its investigational anti-interleukin-15 (IL-15) monoclonal antibody, into a phase 2b clinical trial in patients with non-segmental vitiligo (NSV) during the fourth quarter of 2026.¹

The advancement follows encouraging interim results from an ongoing phase 1b, open-label study in adults with active or stable non-segmental vitiligo, in which TEV-'408 demonstrated early improvements in repigmentation, was well tolerated, and showed no safety signals to date.

TEV-'408 is designed to inhibit IL-15, a cytokine increasingly recognized as a central driver of vitiligo pathogenesis. Unlike currently available therapies that require more frequent administration, the investigational antibody is being developed as a quarterly (every 12 weeks) subcutaneous injection, potentially reducing treatment burden for patients requiring systemic therapy.¹

Encouraging Early Efficacy Signals

The study enrolled adults with active or stable non-segmental vitiligo, approximately two-thirds of whom had disease affecting more than 10% of body surface area—a population with relatively limited treatment options. At week 24, investigators reported encouraging efficacy across both facial and total body disease measures.

Among evaluable participants at week 24, TEV-'408 demonstrated improvements across multiple clinician- and patient-reported outcomes, including:

• Nearly 75% of patients reported improvement in facial vitiligo
• Approximately 50% described their facial vitiligo as "much improved" or "very much improved"
• 42% achieved F-VASI50
• 21% achieved F-VASI75
• 55% reported improvement in total body vitiligo
• 7% achieved T-VASI50

Improvements were most pronounced in facial disease, an outcome that is often prioritized by patients because of its cosmetic and psychosocial impact.

Importantly, approximately 66% of enrolled patients had vitiligo affecting more than 10% body surface area at baseline—a patient population for whom treatment options remain particularly limited.¹²

Designed for Less Frequent Dosing

One of the distinguishing features of TEV-'408 is its prolonged half-life, which supports administration once every 12 weeks.

Current vitiligo treatment options often require daily topical therapy or more frequent systemic administration. A quarterly injectable biologic could offer a more convenient option for patients with extensive disease while potentially improving long-term adherence.

"TEV-'408 exemplifies the type of innovative, Teva-discovered program we are prioritizing as we continue to advance and strengthen our immunology pipeline," Richard Francis, president and chief executive officer of Teva, said in a news release.

The phase 2b study is expected to further evaluate TEV-'408 in a larger population of patients with non-segmental vitiligo following the encouraging phase 1b findings.¹

Targeting a Key Driver of Vitiligo

IL-15 is believed to play a central role in maintaining tissue-resident memory T cells, which contribute to the persistent autoimmune destruction of melanocytes and may help explain why vitiligo often recurs after treatment discontinuation.

By blocking IL-15 signaling, TEV-'408 aims to interrupt the autoimmune process responsible for depigmentation rather than simply stimulating repigmentation.²

"Vitiligo can affect far more than the skin. It can shape how people see themselves, how they show up in the world, and the confidence they carry every day," said Eric Hughes, MD, PhD, executive vice president of global research and development and chief medical officer at Teva.¹

"These encouraging data strengthen our confidence in the IL-15 pathway and reflect the depth of Teva's scientific expertise."

Building on a Growing Vitiligo Pipeline

Interest in systemic therapies for vitiligo continues to accelerate following recent advances in JAK inhibition and other targeted immune therapies. Although topical ruxolitinib remains the only FDA-approved therapy specifically indicated for repigmentation in non-segmental vitiligo, investigators continue to explore systemic approaches targeting immune pathways such as IL-15 for patients with more extensive disease or those seeking more durable disease control. TEV-'408 enters an increasingly active therapeutic landscape that extends beyond JAK inhibition and could represent one of the first biologic therapies specifically designed to interrupt IL-15 signaling while offering the convenience of quarterly dosing.¹²

What's Next?

The ongoing phase 1b study enrolled adults with active or stable non-segmental vitiligo who received TEV-'408 as two subcutaneous injections at baseline and week 12, with efficacy assessed at week 24 using the Vitiligo Area Scoring Index (VASI). Patients will continue to be followed through week 80.

Teva expects to initiate the phase 2b study in the fourth quarter of 2026. Beyond vitiligo, TEV-'408 is also being evaluated in a phase 2a study for celiac disease and received FDA Fast Track designation for that indication in 2025.

If successful, TEV-'408 could expand treatment options for patients with extensive non-segmental vitiligo by offering a potential systemic therapy with convenient quarterly dosing.

References:

1. Teva to advance its anti-IL-15 antibody, designed for quarterly dosing, into phase 2b development in vitiligo, following encouraging phase 1b results. News release. Teva Pharmaceutical Industries. July 7, 2026. Accessed July 7, 2026.
2. Royalty Pharma and Teva enter agreement to accelerate development of potential treatment for vitiligo. News release. Teva Pharmaceutical Industries. December 16, 2025. Accessed July 7, 2026.